Potential biological markers of atrial fibrillation: a chance to prevent cryptogenic stroke by Szegedi, István et al.
Potential biological markers of atrial fibrillation – a chance to prevent 
 
cryptogenic stroke 
 
 
 
 
István Szegedi2, László Szapáry1, Zoltán Csanádi3, László Csiba2 
 
 
 
1University of Pécs, Clinical Centre, Department of Neurology, Pécs, Hungary 
 
2
University of Debrecen, Clinical Centre, Department of Neurology, Debrecen, 
 
Hungary 
 
3
University of Debrecen, Clinical Centre, Department of Cardiology, Debrecen, 
 
Hungary 
 
 
 
 
Word count abstract: 170 
Word count text: 4847 
 
Correspondence: László Csiba MD, PhD, D. Sci., University of Debrecen, Clinical 
Centre, Department of Neurology, Móricz Zsigmond Street 22, Debrecen, H-4032, 
Hungary,e-mail: csiba@med.unideb.hu 
Abstract 
 
 
 
 
Stroke affects millions of people all over the world, causing death and disability. The 
most frequent type of this disease is ischemic stroke, which can be caused by different 
factors. In approximately 25 percent of cases, no obvious cause can be found. Recent 
observations have shown that paroxysmal atrial fibrillation could be responsible for a 
significant number of cryptogenic stroke events. Short or long-lasting ECG monitoring 
could help with the diagnosis of transient arrhythmias. Unfortunately, these techniques 
are either expensive, or require good patient compliance. An alternative option is the 
identification of biological markers that are specific for atrial fibrillation, and can be 
used to predict arrhytmia. In this review we give a summary of the recent advances in 
the research of arrhythmia markers. Based on their structure and function, we 
differentiated four groups of biomarkers: markers of inflammation, markers of fibrosis, 
markers with hormonal activity and other markers. In spite of intensive researches, the 
optimal  biological marker  is still not available, but there are some promising markers, 
like NTproBNP/BNP. 
1. Introduction 
 
 
 
 
Stroke is a common vascular disease manifesting in different subtypes, causing death and 
disability, therefore it is an important challenge for the health care system. After an ischemic 
event a thorough work-up identifies the cause in about 75 percent of cases. In the remaining 
20-25 percent, no causative factor can be found: these are called cryptogenic stroke events. 
In about 25-30 percent of these events, the underlying cause could be paroxysmal atrial 
fibrillation (PAF) (1,2,3). Most studies defined PAF as an event that lasts longer than 30 
seconds, referring to the AHA 2006 guidelines (4). In atrial fibrillation (AF), the blood flow 
in the cavities of the heart is turbulent, which can precipitate thrombus formation and 
embolisation (5). Despite the fact that paroxysmal atrial fibrillation is frequently 
asymptomatic, the risk of stroke is the same as in permanent AF (6). The diagnosis requires 
extended ECG monitoring (eg. Holter ECG, outpatient monitoring (7,8)) of the patient. If a 
cardiogenic mechanism is identified behind a stroke event, anticoagulation is warranted 
instead of antiplatelet therapy (4). Post-stroke patients, however are not optimal candidates 
for long-lasting ECG monitoring (insufficient compliance, frequent falls, aphasia, limb 
paresis, etc.). There is an increasing need for blood biomarkers that are capable of identifying 
patients at significant risk of PAF. Currently the optimal marker is still unknown. An ideal 
biological marker has the following characteristics: high sensitivity, high specifity, high 
predictivity and rapid, simple, accurate, inexpensive and reproducible detection in all relevant 
patients. In this review article we aimed to summarize the most important recent observations. 
2. Methods 
 
 
 
 
PUBMED, EMBASE, BIOMED RESEARCH INTERNATIONAL, AND GOOGLE SCHOLAR 
were searched for published studies. We examined studies that have presented data on association 
between atrial fibrillation and biological markers We used the keywords „atrial fibriallation”, 
„biological marker” „stroke” and the name of the markers. Based on their structure and 
function, four groups of biomarkers can be differentiated: markers of inflammation, markers 
of fibrosis, markers with hormonal activity and other markers. 
 
 
3. Markers of inflammation 
 
 
 
 
In the last few years, a number of trials have concluded that AF is triggered by inflammation, 
resulting in electrical and structural remodeling (9,10). Active inflammation can provoke AF, 
that in return causes an inflammatory response that further enhances atrial remodeling, 
resulting in arrhythmia – the so-called ‘AF begets AF’ phenomenon. The progress is similar 
to a spiral: inflammation begets AF, and AF begets inflammation (11). 
 
A promising new inflammatory marker is pentraxin 3 (PTX3), a member of the long pentraxin 
family. The C-terminal sequence of PTX3 is homologous with serum amyloid P component 
and the classic short pentraxin CRP. PTX3 is produced in large amounts by different cells 
(e.g. monocytes, macrophages and endothelial cells) in local inflammatory lesions, whereas 
CRP is mostly produced by the liver (12). 
 
A subgroup of 382 patients, who were selected from 36 centres with AF in their history but 
in sinus rhythm at randomization, was enrolled in the GISSI-AF biohumoral study that 
investigated the association between the plasma concentrations of pentraxin-3 (PTX3), high-
sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6), the echocardiographic findings 
and the time of the first return of AF (13). Recurrent AF developed in 204 patients during the one 
year long follow-up. Baseline plasma concentrations of IL-6, hsCRP and PTX3 were measured 
and they found no significant differences between patients with or without recurrent AF. At 6 and 
12 months of follow-up, IL-6 and PTX3 concentrations were significantly higher in patients with 
AF compared to those who were in sinus rythm, and the hsCRP levels were higher in patients 
with the most recent episodes of AF. Baseline levels of PTX3, IL-6 and hsCRP were not 
significantly associated with a higher risk of AF recurrence. These markers can be elevated in AF 
patients, but they were found to be weak predictors of arrhythmia recurrence in this study. 
 
 
The neutrophil to lymphocyte ratio (NLR) is a major marker of subclinical inflammation, and 
it is a widely investigated marker recently used in the prediction of cerebrovascular diseases 
(14,15). 
 
Ertaş et al. carried out a retrospective study on 126 consecutive non-valvular AF patients with 
or without thromboembolic stroke (16). A group of 24 patients in sinus rhythm served as a 
reference point for the comparison with the AF group. Based on NLR values at admission the 
study population was divided into tertiles. A low NLR level (n=84) was defined as a value in 
the lower two tertiles and high NLR level (n=42) was defined as a value in the third tertile. 
Stroke rates and CHADS2 scores were found to be significantly higher in the high NLR group 
compared to the low NLR group. Stroke patients had significantly higher mean white blood 
cell (WBC) counts and NLR values. Therefore, NLR can be used in patients with non-valvular 
AF as an independent predictor of thromboembolic stroke.
A cohort study conducted by Saliba et al. aimed to find the association between NLR, atrial 
fibrillation and stroke (17). 32 912 adult patients with AF, no anticoagulation therapy at the 
baseline, and without previous stroke or TIA were analyzed retrospectively in a computerized 
database. The patients were followed for the first occurence of stroke or TIA from 1 January 2012 
until 31 December 2012. 981 subjects developed stroke during a follow-up of 30 961 person-
years (stroke rate, 3.17 per 100 person-years). The patients were grouped into quartiles based on 
NLR levels. The incidence rate of stroke increased in a dose-response manner across NLR 
quartiles, therefore the study showed that there is a significant association between NLR level and 
the first episode of stroke in patients with atrial fibrillation. 
 
 
Based on these studies NLR is a promising marker in predicting paroxysmal AF, while the 
usefulness of PTX3 is questionable (Table 1). 
 
 
4. Markers of fibrosis 
 
 
 
 
Galectin-3 (Gal-3) is a β-galactoside–binding lectin that seems to play a major role in the 
regulation of fibrosis and inflammation (18). 
 
Ho et al. investigated the relation between plasma galectin-3 concentrations and the incidence 
of AF. Plasma levels of the peptide were measured in 3.306 members of the Framingham 
Offspring cohort (who paticipated in the sixth examination cycle between 1995-1998) (19). 
They used Cox proportional hazards regression models to evaluate the association between 
baseline Gal-3 concentrations and the incidence of AF. They found that elevated Gal-3 plasma 
levels were associated with a higher risk of developing AF, but after adjusting for clinical risk 
factors to predict AF risk, the association was no longer significant (20). 
 
An observational study managed by Gurses et al. also aimed to find the correlation between 
plasma galectin-3 levels and atrial fibrillation (21). Seventy-six patients with paroxysmal or 
persistent AF and preserved left ventricular systolic function and 75 age- and gender-matched 
control patients were enrolled in the study. All of them underwent transthoracic 
echocardiographic examination (TTE) to measure left atrium (LA) size and left ventricular 
(LV) function to exclude any structural disease of the heart. LA volume index (LAVI) was 
calculated on the basis of the patient’s body surface area. Galectin-3 level was measured and 
it was significantly elevated in patients with AF in comparison with the control group. Serum 
galectin-3 levels were also significantly higher in patients with persistent AF than in those 
with paroxysmal AF. Multivariate regression analysis was performed demonstrating that 
serum galectin-3 levels and LAVI were independent predictors of AF. They found an 
independent correlation between LAVI and serum galectin-3 levels in patients with AF 
through linear regression analysis.  
The observational study of Yalcin et al. was very similar, but this investigation was conducted 
using delayed enhancement magnetic resonance imaging (DE-MRI) to estimate the degree of 
atrial fibrosis, and atrial electromechanical delay (AEMD), a non-invasive echocardiographic 
method to measure inter- and intra-atrial conduction delays (22). Thirty-three patients with 
paroxysmal AF and unimpaired LV function were enrolled. The study demonstrated that 
serum galectin-3 levels had an independent correlation with the extension of LA fibrosis 
demonstrated by DE-MRI in paroxysmal AF patients. Serum galectin-3 levels also had a 
correlation with intra-left and inter-AEMD, which is really important because they are 
accepted as noninvasive echocardiographic markers of atrial electrical remodeling. 
 
TGF-b1 is expressed in endothelial cells, vascular smooth muscle cells and myofibroblasts 
(23). In the heart, TGF-b1 seems to be a factor that causes different diseases by inducing 
cardiac fibrosis, based on studies examining overexpression and knockout models (24). In a 
mice study the animals with increased expression of TGF-b1 were prone to develop atrial 
fibrillation as a result of a higher degree of atrial fibrosis (25). 
 
TGF-b1 levels seem to be increased in humans with atrial fibrillation as well. In a study, Lin et 
al. examined the relation between TGF-β1 and atrial fibrillation in patients with essential 
hypertension (EH) (26). 75 patients with AF secondary to EH were selected in the study and then 
divided into 2 subgroups: the paroxysmal AF group (pAF) consisting of 44 patients and the 
chronic AF group (cAF) consisting of 31 patients. 37 EH patients with sinus rhythm (SR) were 
selected into the EH+SR control group and 36 healthy subjects were assorted as normal controls 
(NC group). Clinical characteristics of the patients were collected and TTE examinations were 
also performed. Blood samples were taken in the morning from fasting and resting subjects for 
the assessment of TGF- β1 and CTGF (connective tissue growth factor) levels. TGFβ1 and CTGF 
serum levels were significantly higher in the EH groups than in the NC group. TGFβ1 and CTGF 
levels were highest in the cAF group, followed by the pAF and SR groups. They didn’t find 
significant differences in TGFβ1 and CTGF levels between the pAF group and the cAF group. In 
AF patients, there was an independent correlation between serum levels of TGFβ1 and left atrial 
diameter (LAD), the presence of AF, aldosterone, CTGF and age. As a possible conclusion, serum 
TGFβ1 was found to indicate the synthesis of CTGF causing enlargement and remodeling of the 
left atrium, which can lead to AF in EH patients. 
 
Matrix metalloproteinase 9 (a member of the matrix metalloproteinase family) is an 
endopeptidase, synthesized and secreted in monomeric form as zymogen. It can degrade 
components of the extracellular matrix and it also takes part in various physiological and 
pathological processes including development, growth, reproduction, furthermore, vascular, 
proliferative and inflammatory diseases (27). 
 
In their study, Li et al. measured not only the plasma level of MMP9, but they also 
investigated its significance in different stages of idiopathic AF (28). The patients were 
categorized into 3 groups: paroxysmal AF, persistent AF and permanent AF groups, each 
containing 25 patients. The control group consisted of 40 healthy individuals. Venous blood 
samples were taken. MMP-9 plasma levels in the AF-groups showed significant elevation 
compared to the control group. From paroxysmal AF through persistent AF to permanent AF 
the plasma levels of MMP9 showed a significant gradual increase. 
 
 
The Growth/differentiation factor 15 (GDF15) protein is a member of the transforming 
growth factor beta superfamily. It has several physiological functions including the regulation 
of proliferation and apoptosis in normal, injured, and transformed cells, but it also has 
pathological functions such as growth inhibition and overexpression in cancer cells (29). 
 
Shao et al. aimed to find the correlation between the serum levels of GDF-15, NRG-1 and 
nonvalvular AF. Their study included 67 patients with nonvalvular AF and 67 healthy persons 
matched for age, sex and atherosclerotic risk factors (30). They collected baseline demographic 
and clinical characteristics, and performed TTE. They measured the plasma levels of GDF15, 
NRG-1 (a member of the epidermal growth factor (EGF) gene family playing a role in growth, 
cell survival, cardiovascular development, and metabolism (31)) and other basic laboratory 
parameters. Patients from the AF group had higher GDF-15, NRG-1 levels and LAD values 
than non-AF patients. Patients with paroxysmal AF had a significantly higher serum level of 
GDF-15 compared to the control group. Likewise, NRG-1 levels were also higher in 
paroxysmal AF patients. According to multivariable analyses, GDF-15 was independently 
associated with paroxysmal AF. 
 
Sonmez et al. examined a study population consisting of 52 patients diagnosed with non-
valvular AF and 33 age-matched subjects without AF in their history (32). Their goal was to 
compare the serum levels of novel biomarkers between a group of AF patitents and a group 
of healthy individuals. These markers were Galectin-3, MMP-9, lipocalin-2 (NGAL, a novel 
adipokine associated with insulin resistance (33)), PIIINP (the amino-terminal peptide of 78 
procollagen type III, released into the blood during both synthesis and degradation of collagen 
type III (34)), Hs-Crp and NLR. Correlation analyses found a significant correlation between 
NLR and LAVI (left atrial volume index), but not between Hs-CRP and LAVI. There was a 
strong correlation between Galectin-3, MMP-9, PIIINP and LAVI. MMP-9, Galectin-3, and 
PIIINP levels were significantly higher in AF patients, but NGAL levels were not. NLR and 
Hs-CRP levels were also elevated in AF patients. 
 
 
As a part of the Cardiovascular Health study, Rosenberg et al. assessed the plasma levels of 2 
fibrosis biomarkers, PIIINP and TGF-β1 (35). PIIINP levels were measured in 2,935 participants, 
of whom 767 patients developed AF. PIIINP levels showed a nonlinear relationship with the risk 
of incident AF both before and after risk adjustment. A linear relationship was observed between 
the risk of AF and PIIINP levels approximately up to the median value, but unfortunately no 
significant association was identified beyond that point. TGFβ1 levels were assessed in 1,538 
individuas with 408 cases of incident AF, but this marker’s levels were not associated with 
AF risk. No association was found between TGF-β1 levels and the incidence of AF in 
unadjusted or adjusted models. 
 
 
To summarize, Galectin 3, MMP9, GDF15 and PIIINP are promising markers in the 
prediction of paroxysmal AF, while TGF-β1 shows less potential (Table 2). 
 
5. Markers with hormonal activity 
 
 
 
 
Natriuretic peptides (NPs) are produced in the heart and released into the circulation in response 
to pressure and volume overload. NP levels provide information about the systolic and diastolic 
function as well as the right ventricular and valvular function (36). In recent years, different NPs, 
such as brain natriuretic peptide (BNP), its N-terminal prohormone (NT-proBNP) and atrial 
natriuretic peptide (ANP) emerged as possible biological markers of atrial fibrillation. The 
connection between BNP and/or NT-proBNP has been investigated by numerous studies. Silvet 
et al. measured BNP levels in 72 outpatients with chronic atrial fibrillation (AF) and in 49 control 
subjects without AF. BNP levels were significantly higher in patients with AF (37). Another study 
was performed at the Kagawa University School of Medicine Hospital that aimed to measure 
BNP levels in patients with acute ischemic stroke (38). This cohort included 99 patients with 
acute cerebral infarction. 23 patients were excluded due to having myocardial infarction, heart 
failure, valve disease or chronic renal failure. 36 of the remaining patients developed 
cardioembolic stroke with atrial fibrillation (23 with permanent and 13 with paroxysmal atrial 
fibrillation); and 40 had non-cardioembolic stroke. BNP was evaluated on the first morning after 
admission, and TTE was also performed. In the cardioembolic stroke/atrial fibrillation group, 
plasma BNP levels, LAD and the ratio of peak early filling velocity to peak atrial systolic 
velocity (E/A) were significantly increased, while left atrial appendage flow was significantly 
reduced compared to non-cardioembolic stroke patients. First-day BNP and LAA flow were 
useful in differentiating cardioembolic stroke with AF from non-cardioembolic stroke. 
 
In the Cardiovascular Health Study (CHS), Patton et al. found a connection between AF and 
NT-proBNP (39). NT-proBNP levels were measured in 5,447 patients (2 of them were 
excluded due to missing baseline ECG results). NT-proBNP levels showed a strong 
association with prevalent AF. After a median follow up of 10 years (maximum of 16 years), 
1.126 cases of incident AF were registered (a rate of 2.2 per 100 person years). NT-proBNP 
levels proved to be greatly predictive of incident AF. 
 
Within the settings of the Multi-Ethnic Study of Atherosclerosis (MESA), 5518 patients were 
enrolled to investigate a possible association between serum NT-proBNP levels and AF (40). 
NT-proBNP levels were measured from frozen serum samples drawn at enrollment. The 
associations between NT-proBNP and gender, age and ethnicity/race were also investigated. 
They followed the patients for a median of 7.6 years. During this time, 267 of them developed 
AF. The average NT-proBNP level was higher in subjects with AF. NT-proBNP was 
statistically significantly associated with incident AF. 
 
Kara et al. investigated the association of BNP with incident AF in a large population-based 
cohort study (41). The patients didn’t have a history of prior stroke, coronary heart disease, 
heart-device therapy, open heart surgery or prevalent AF at baseline. 3067 subjects were 
involved in the logistic regression analysis. They examined the association of BNP as a 
continuous and binary variable (with predefined gender-specific BNP thresholds) with new onset 
of AF as well as its value for risk prediction beyond traditional AF risk factors. Higher BNP levels 
showed association with excessive incidence of AF, e.g. resulting in a four-fold risk in a five-year 
period for subjects with a BNP level over 31 pg/ml for men and 45 pg/ml for women in the crude 
model. After adjustment for traditional AF risk factors and CAC (coronary artery calcium) the 
association stayed statistically significant. The associations were more explicit in younger 
patients. To summarize these results: elevated levels of BNP were found to be associated with 
significant excess of incident AF independently of traditional risk factors of AF in the general 
population. In the future the gender-specific BNP thresholds may help in the detection of subjects 
with unknown or future AF that can lead to stroke events. 
 
Rodríguez-Yáñez et al. performed an interesting prospective study enrolling patients with 
cryptogenic stroke from February 2008 to July 2011 according to the TOAST criteria (42). 
Of the evaluated 1.050 patients, 264 were qualified for the study. Blood samples were taken 
within the first 24 hours from the onset of the stroke for the measurement of pro-BNP levels. 
Then the patients were followed up at 3 and 6 months by a neurologist, and later by a primary 
care physician for 2 years in order to register the development of AF. Fifteen patients (5.6%) 
developed AF during the follow-up period. Patients who developed AF were older and more 
frequently had a history of hypertension. Forty-eight patients (18.2%) died during the follow-
up period. Higher NT-pro-BNP levels were detected in patients who developed AF, compared 
with those who did not. Based on these findings, high NT-proBNP levels measured during 
the acute phase of stroke in cryptogenic stroke patients are associated with a five-fold increase 
in the risk of developing AF in the following 2 years. 
 
The TARGET AF was a prospective cohort study of stroke survivors performed in the stroke 
center of the Nice Univesity Hospital, that aimed to identify a relevant marker of delayed AF 
in the selected patients in whom AF was detected by early and prolonged monitoring (43). 
373 patients were included in the study and 53 of them were excluded due to diagnosis of AF 
at baseline. 20 patients with sinus rhythm at baseline but with AF in their history were also 
excluded. Plasma BNP was measured in blood samples taken at admission. Holter ECG 
monitoring was started immediately at admission and was stopped at discharge in all patients. 
Newly diagnosed AF was documented in 52 patients (AF prevalence of 17.33%) suggesting 
the association of early and prolonged monitoring with an increased AF detection rate. Plasma 
BNP values were significantly higher in patients with AF. The use of all examined parameters 
together didn’t provide significant additional diagnostic value over BNP (diagnostic 
properties of BNP level: sensitivity: 98.08%; specificity: 71.37%; negative predictive value: 
99.4%). The most important result of the study is that BNP level has a really strong negative 
predictive value in stroke patients that can be related to delayed AF. 
 
 
Fibroblast growth factor-23 (FGF-23) is a bone-derived hormone that plays an important role 
in the homeostasis of phosphate. FGF-23 reduces gastrointestinal phosphate absorption, 
inhibits the production of 1,25-dihydroxyvitamin D and promotes urinary phosphate 
excretion (44,45). 
 
Mathew et al. examined participants from The Multi-Ethnic Study of Atherosclerosis (MESA) 
and the Cardiovascular Health Study (CHS) to investigate the relation between FGF-23 and AF. 
6398 patients were from the MESA study, and 1350 participants were from the CHDS study (46). 
Incident AF was identified using inpatient and outpatient physician claims data, systematic 
reviews of hospital discharge diagnoses, and study ECGs over 7.7 and 8.0 years of median 
follow-up. Cox proportional hazard models were used to test associations between FGF-23 
and the risk of developing AF. A series of multivariable models were also constructed. In 
MESA participants 291, while in CHS participants 229 incident AF events were observed. In 
both MESA and CHS participants higher FGF-23 concentrations were associated with higher 
unadjusted incidence rates of AF. Later adjustments for demographics and potential 
confounding characteristics were carried out. In these analyses, each two-fold higher FGF-23 
concentration was associated with a 41% higher risk of AF in MESA patients and a 29% 
higher risk of AF in CHS patients, proving that higher circulating FGF-23 concentrations 
increase the risk of incident AF. Other biomarkers of mineral metabolism, eGFR, urine ACR 
and heart failure events were also accounted for, and the associations remained significant. 
Adjusting for FGF-23 attenuated the association of low eGFR with incident AF in MESA 
patients, suggesting that FGF-23 may mediate, in part, the known association of CKD with 
AF. 
 
 
NT-pro BNP (and BNP) were found to be elevated in AF by several studies. Studies that 
evaluated the connection of the natriuretic peptid with AF in cryptogenic stroke patients were 
also performed, determinig well-defined cut-off values that are able to predict paroxysmal 
events in cryptogenic patients. FGF-23 is also a promising marker, but currently we don’t 
have enough infomation about it (Table 3). 
 
 
 
 
6. Markers with other functions 
 
 
 
 
Circulating procoagulant microparticles (MPs) are small membrane vesicles that are derived 
from different cells (e.g. platelets, endothelial cells, leukocytes, lymphocytes, erythrocytes) 
in response to activation, injury, and/or apoptosis (47). Platelet microparticles (PMPs) are 
procoagulant membranous vesicles produced by activated platelets. PMP levels are elevated 
in stroke, coronary artery disease (CAD), hypertension and diabetes. 
 
Choudhury et al. aimed to find the correlation between serum platelet microparticle levels 
and non valvular atrial fibrillation (48). The study had 3 hypotheses: {1} PMP levels are 
higher in patients with AF compared to levels in both disease control subjects (i.e. patients 
with diabetes or stroke, CAD, hypertension who are in sinus rhythm) and healthy control 
subjects (i.e. patients without cardiovascular diseases who are in sinus rhythm); {2} PMP 
levels correlate with levels of soluble P-selectin (sP-selectin) which is a platelet activation 
marker; and {3} in patients with AF, PMP levels are related to the underlying factors that 
contribute to the comprehensive risk of stroke secondary to AF. The study team performed a 
case-control study of 70 AF patients, 46 disease control and 33 healthy control patients. The 
levels of PMPs and sP-selectin were significantly higher in both AF patients and disease control 
subjects compared to healthy control subjects, but no difference was found between AF patients 
and disease control subjects. There wasn’t any difference in PMP levels between patients with 
paroxysmal and permanent AF, and between those who receive antiplatelet or anticoagulant 
therapy (aspirin and warfarin, respectively). A significant correlation wasn’t observed between 
PMP and sP-selectin levels and the clinical characteristics that contribute to the elevated risk of 
stroke in patients with AF. Through multiple regression analysis in the combined cohort of AF 
patients and the disease control subjects the presence/absence of AF did not prove to be an 
independent determinant of PMP and sP-selectin levels.  
Ederhy et al. also suggested that procoagulant MP levels in the circulation would be increased 
in AF, so they elaborated a hospital-based case-control study design, involving 45 patients 
with AF and 90 control subjects: 45 with cardiovascular risk factors and 45 without (49). The 
levels of 3 different MPs were screened: platelet-derived MPs, annexin V-positive MPs and 
endothelial-derived MPs. Annexin V-positive MP levels were elevated in patients with AF 
compared with control subjects with and without cardiovascular risk factors. The levels of 
platelet-derived MPs and endothelial-derived MPs were similar in patients with AF and 
control subjects with cardiovascular risk factors, but were significantly higher than in control 
subjects without cardiovascular risk factors. Finally, the presence of AF strongly predicted 
annexin V-positive MP levels. Based on these data, circulating procoagulant MPs can be 
increased in persistent and/or permanent AF and might indicate a hypercoagulable state that 
could lead to atrial thrombosis thus thromboembolism. 
 
 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase 
(NOS) capable of causing NO deficiency and an increased risk of thrombosis (50). Cengel et al. 
investigated patients in three gropus: 17 patients whose AF was detected for the first time within 
the first 24 hours of presentation (group 1), 25 patients with permanent chronic AF lasting at least 
1 year or more (group II) and 18 healthy people as the control group (group III) (51). Plasma 
ADMA, SDMA and L-arginine concentrations were compared. In patients with acute onset of 
AF, ADMA levels were significantly higher when compared to patients with chronic AF and the 
healthy control group. ADMA levels were higher in all patients with AF than in the control group 
of healthy people. This information indicates that endothelial dysfunction and a 
prothrombotic state develop in a very early phase of AF. 
 
 
MicroRNAs (miRNAs) are a class of 19–25-nucleotide non-coding RNAs with a broad spectrum 
of functions including the regulation of cellular differentiation, proliferation, development and 
death (52). Different miRNAs with different functions are known, and they are widely 
investigated, but their value as blood biomarkers is still not clear. 
 
In a study conducted by Zheng et al., 105 patients were enrolled for miRNA investigation (53). 
15 participants were selected for n-depth sequencing of plasma miRNAs: 5 people with 
paroxysmal AF, 5 with persistent AF and 5 healthy individuals. The other 90 participants were 
randomly classified as testing using quantitative reverse transcriptase–polymerase chain reaction 
(qRT–PCR). Blood samples were taken from all enrolled patients to carry out the in-depth 
analysis. Massively parallel signature sequencing (MPSS) was also performed. 22 specific 
miRNAs showed dysregulation in each group. Four candidate microRNAs (miRNA-375, 
miRNA-146a, miRNA-19a and miRNA-150) were suitable for further investigation in an 
independent cohort of 90 plasma samples using TaqMan miRNA quantitative reverse 
transcriptase–polymerase chain reaction (qRT-PCR). The expression levels of these miRNAs 
were significantly downregulated in patients with AF, but only miRNA-150 demonstrated 
significant charachteristic changes. Its expression levels were reduced by a factor of 
approximately 17 times in PAF patients relative to controls and a factor of approximately 20 times 
in PersAF relative to controls. Based on the the median expression results of miRNA-150, no 
significant differences were found between the levels of miRNA-150 among the healthy controls, 
PAF patients, and PersAF patients. Moreover, no correlation was found between miRNA-150 
levels and the presence or absence of antiarrhythmic drug therapy in AF patients. MiRNA-
150 levels were independently associated with age and LAD. Parallel plasma CRP 
measurements showed that the levels of CRP were negatively correlated with the plasma 
levels of miRNA-150. 
 
McManus et al. analyzed the association between circulating miRNAs and AF (54). 2445 
individuals from the Framingham Heart Study (FHS) Offspring study were enrolled. The 
expression of 385 miRNAs isolated from whole blood was measured using TaqMan chemistry-
based assays. After the measurement and statistical analysis, the expression of several miRNAs 
(miR-150-5p, miR-328, miR-331-3p and miR-28-5p) were found to be negatively associated with 
prevalent AF. After adjustment for age, sex, isolation batch, RNA quality, concentration and 
260/280 ratio, the association with AF remained significant only with miR-328, which was found 
in a relatively high amount in patients. Unfortunately, after further adjustments for clinical AF 
risk factors linked to atrial size and/or pathological atrial remodeling, including weight, height, 
systolic and diastolic blood pressure, antihypertensive medication (including beta-blocker) use, 
current smoking, prevalent heart failure, myocardial infarction and diabetes mellitus, this 
association was attenuated.The assocation between higher miR-328 and AF is really interesting, 
because this miRNA promotes atrial electrical remodeling, thus AF by reducing L-type Ca2+ 
channel density (55). 
 
 
The potential in using PMPs and ADMA as predictors of AF is promising. Micro RNAs are 
quite intriguing, because they have lot of different types, thus a lot of potential, but more 
investigation is needed in the future (Table 4). 
 
7. Conclusion 
 
The investigated markers have different functions, some of them are connected to 
inflammation (NLR, pentraxin 3, CRP, IL6), while others contribute to the fibrosis of the 
atrium (MMP9/TIMP, TGF β1, PIIINP, galectin, CTGF). (Inflammation and fibrosis go hand 
in hand, so the separation of these markers can be difficult sometimes). Some markers have 
a characteristic hormonal effect (NT-pro BNP, FGF23), and we can find markers that play a 
role in protein catabolism (ADMA) or post-transcriptional changes (micro RNA), but there 
are some markers with complex functions and structure as well (circulating procoagulant 
microparticles). Most of the analyzed markers have promising data, but at present none of 
them fulfills the criteria of an optimal biomarker. NT-pro BNP/BNP are the most promising 
candidates. 
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Table 1. Markers of inflammation 
 
 
+- questionable, + potentially useful, ++ very promising, ↑ increased, ↓decreased, ⃠ no 
 
Biomarker 
 
 
Trials 
 
Patients 
 
Results 
Potential DX 
efficiency in 
cryptogenic stroke 
 
Pentraxin 3 
 
1 prospective trial 
 
382 
weak predictor 
of the 
recurrence of 
AF. 
 
+- 
 
NLC 
 
2 retrospective 
trials 
 
126/32912 
useful in 
predicting stroke 
in patients with 
known AF 
 
+ 
 
 
 
Table 2. Markers of fibrosis
 
+- questionable, + potentially useful, ++ very promising, ↑ increased, ↓decreased, ⃠ no 
 
 
 
 
 
 
 
 
 
 
Biomarker 
 
Trials 
 
Patients 
 
Results 
Potential DX 
efficiency in 
cryptogenic stroke 
 
 
 
 
 
 
galectin 3 
 
1 
prospective 
trial 
 
1 
prospective 
trial 
 
1 
prospective 
trial 
 
 
3306 
 
 
 
76 
 
 
 
33 
 
 
 
↑Gal-3: ↑ risk of developing AF 
after adjusting for clinical risk 
factors:   ⃠   significant 
 
galectin-3 ↑ in AF than in the control 
galectin-3 ↑in persistent AF than in 
paroxysmal AF 
 
galectin- 3 level is an independent 
correlate of the extent of LA fibrosis 
in paroxysmal AF patients 
 
 
 
 
 
 
+ 
 
 
TGFβ1 
 
1 
prospective 
trial 
 
 
75 
TGFb1 ↑ in cAF and pAF group than 
in SR group 
⃠ difference in TGFb1 levels between 
the cAF group and the pAF group 
 
 
+- 
 
 
MMP9 
1 
prospective 
trial 
 
 
75 
 
MMP9 levels ↑ gradually from 
paroxysmal AF through persistent AF, 
permanent AF. 
 
+ 
 
GDF15 
1 
prospective 
trial 
 
 
67 
 
GDF-15 ↑ in paroxysmal AF 
independently associated with 
paroxysmal AF. 
 
+ 
 
 
 
Multimarker 
1 
prospective 
trial 
 
1 
prospective 
trial 
 
52 
 
 
 
2935 
 
 
Galectin-3, MMP-9, and PIIINP ↑ in 
AF 
 
PIIINP showed a nonlinear association 
with incident AF, ⃠association 
between circulating TGF-β1 levels 
and incident AF. 
 
 
 
+ 
 
 
 
Table 3. Markers with hormonal activity 
+- questionable, + potentially useful, ++ very promising, ↑ increased, ↓decreased, ⃠ no 
 
 
 
 
 
 
Biomarker 
 
 
Trials 
 
Patients 
 
Results 
Potential DX 
efficiency in 
cryptogenic stroke 
 
 
 
 
 
 
 
 
 
 
 
 
 
NT-pro 
BNP/BNP 
1 
prospective 
trial 
 
1 
prospective 
trial 
 
 
1 
prospective 
trial 
 
1 
prospective 
trial 
 
1 
prospective 
trial 
 
 
1 
prospective 
trial 
 
 
1 
prospective 
trial 
72 
 
 
 
 
76 
 
 
 
 
5445 
 
 
 
5518 
 
 
 
3067 
 
 
 
 
264 
 
 
 
 
300 
↑ BNP levels in patients with AF than 
without AF 
 
 
First-day BNP and LAA flow are 
helpful in differentiating cardioembolic 
stroke with AF from noncardioembolic 
stroke 
 
NT-proBNP was an important predictor 
of incident AF, also after adjustment 
for covariates 
 
NT proBNP was significantly 
associated with incident AF and strong 
predictor of it 
 
↑ BNP levels were associated with 
significant excess of incident AF and 
independent of traditional AF risk 
factors 
 
↑ proBNP levels determined during the 
acute phase of stroke ↑ by 5-fold the 
risk of developing AF in cryptogenic 
stroke patients in the following 2 years. 
 
BNP level has a really strong negative 
predictive value in patients stroke that 
can be related to AF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
++ 
 
 
 
 
 
 
 
 
 
 
FGF23 
 
 
1 
prospective 
trial 
 
 
 
 
7748 
 
FGF-23 concentrations were associated 
with higher unadjusted incidence rates 
of AF 
↑ FGF-23 concentration ↑ the risk of 
incident AF. 
 
 
 
+ 
 
 
 
Table 4. Markers with other functions 
+- questionable, + potentially useful, ++ very promising, ↑ increased, ↓decreased, ⃠ no 
 
 
Biomarker 
 
 
Trials 
 
Patients 
 
Results 
Potential DX 
efficiency in 
cryptogenic stroke 
 
 
 
 
 
 
 
 
Circulating 
procoagulant 
microparticles 
 
 
 
 
1 prospective 
trial 
 
 
 
 
 
 
 
1 prospective 
trial 
 
 
 
 
70 
 
 
 
 
 
 
 
 
45 
↑ PMPs  in both AF patients and 
disease control subjects 
compared to healthy control 
subjects,  ⃠difference between 
AF patients and disease control 
subjects.  ⃠difference in PMP 
levels between patients with 
paroxysmal and permanent AF, 
and between those receiving 
anticougulant therapy. 
 
Circulating procoagulant MPs 
can be ↑ in persistent and/or 
permanent AF and might reflect 
a hypercoagulable state that 
could lead to atrial thrombosis 
and thromboembolism. 
 
 
 
 
 
 
 
 
 
 
+ 
 
 
ADMA 
 
 
1 prospective 
trial 
 
 
42 
 
ADMA levels in patients with 
acute AF ↑compared to patients 
with chronic AF and the healthy 
controls 
 
 
 
+ 
 
 
 
 
 
 
micro RNA 
 
 
 
1 prospective 
trial 
 
 
 
 
 
1 prospective 
trial 
 
 
 
10 
 
 
 
 
 
 
 
2445 
The expression levels of these  4 
miRNAs  ↓ in patients with AF. 
The miRNA-150 levels ↓ by a 
factor of approximately 17 times 
in paroxysmal AF patients 
relative to controls and a factor 
of approximately 20 times in 
persistent AF relative to controls 
 
Circulating levels of miR-328 
were associated with prevalent 
AF adjustment for risk factors 
that promote atrial remodeling 
attenuated the association 
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